Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on MRNS. Cantor Fitzgerald restated an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Stock Performance

NASDAQ MRNS opened at $0.55 on Monday. The firm’s 50 day moving average price is $0.54 and its two-hundred day moving average price is $0.79. The stock has a market cap of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $9.69.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in shares of Marinus Pharmaceuticals during the fourth quarter worth approximately $36,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Marinus Pharmaceuticals during the 4th quarter worth about $54,000. World Investment Advisors LLC acquired a new stake in Marinus Pharmaceuticals in the third quarter worth $104,000. Deltec Asset Management LLC bought a new position in Marinus Pharmaceuticals during the fourth quarter worth about $107,000. Finally, XTX Topco Ltd grew its position in shares of Marinus Pharmaceuticals by 1,564.7% in the 4th quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 206,614 shares during the period. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.